# Pravastatin Reduces Acute Phase Response of Zoledronic Acid

> **NCT04719481** · PHASE4 · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 110 (estimated)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Pravastatin Sodium 80 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04719481
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11
- **Primary completion:** 2021-11
- **Final completion:** 2022-04
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2021-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04719481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04719481, "Pravastatin Reduces Acute Phase Response of Zoledronic Acid". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04719481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*